Literature DB >> 17689955

Health-related quality of life and health care utilisation among older long-term cancer survivors: a population-based study.

Floortje Mols1, Jan Willem W Coebergh, Lonneke V van de Poll-Franse.   

Abstract

BACKGROUND: The consequences of cancer and its treatment on health-related quality of life (HRQL) and health care utilisation among elderly long-term cancer survivors have rarely been studied. However, the impact can be different for older compared to younger patients due to the higher prevalence of comorbid diseases, a higher risk of treatment-related complications and because they often receive different therapies compared to younger patients. Therefore, this study addressed the following questions; do HRQL and health care utilisation differ between younger and elderly cancer survivors, and are those differences age or disease related.
METHODS: A population-based, cross-sectional survey among 1893 long-term survivors of endometrial cancer, prostate cancer and non-Hodgkin's lymphoma was conducted using a cancer registry. HRQL was measured by the SF-36 and health care utilisation was measured with a self-reported questionnaire. Results were compared to a normative population. Patients with disease progression were excluded resulting in a total number of 1112 patients to be analysed.
RESULTS: Young non-Hodgkin lymphoma survivors (<70 years) reported lower vitality, bodily pain and general health compared to the normative population while older (70 years) survivors did not differ from the norm. Young lymphoma survivors experienced better physical functioning compared to older survivors. Young endometrial cancer survivors experienced less bodily pain compared to the normative population while older survivors did not differ from the norm. Young endometrial cancer survivors experienced better physical and role functioning compared to older survivors. Young prostate cancer survivors reported less bodily pain compared to the norm while older survivors did not. Young prostate cancer survivors reported higher scores on physical functioning compared to older survivors. Age, comorbid diseases, educational level and current occupation influenced HRQL significantly. Both younger and older cancer survivors visited their medical specialist, but not their GP, significantly more often compared to the age-matched general Dutch population. Both younger and older cancer survivors only sporadically used additional care services after cancer treatment. DISCUSSION: HRQL of older and younger survivors is comparable, with the exception of physical functioning which is lower in older survivors. This difference in physical functioning was probably not caused by cancer because physical functioning among cancer survivors did not differ much compared to an age-matched normative population. Both younger and older long-term cancer survivors visited their medical specialist often but only sporadically used additional care services after cancer treatment.

Entities:  

Mesh:

Year:  2007        PMID: 17689955     DOI: 10.1016/j.ejca.2007.06.022

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  14 in total

1.  Healthcare utilization in men with poorer sexual and urinary function recovery following robot-assisted radical prostatectomy.

Authors:  Peter A Elliott; George A Abdelsayed; Patrick S Kilday; Brian J Kim; Jeff M Slezak; Gary W Chien
Journal:  World J Urol       Date:  2017-10-30       Impact factor: 4.226

2.  Social-cognitive theory predictors of exercise behavior in endometrial cancer survivors.

Authors:  Karen Basen-Engquist; Cindy L Carmack; Yisheng Li; Jubilee Brown; Anuja Jhingran; Daniel C Hughes; Heidi Y Perkins; Stacie Scruggs; Carol Harrison; George Baum; Diane C Bodurka; Andrew Waters
Journal:  Health Psychol       Date:  2013-02-25       Impact factor: 4.267

3.  A comparative analysis of the health and well-being of cancer survivors to the general population.

Authors:  Olinda Santin; Moyra Mills; Charlene Treanor; Michael Donnelly
Journal:  Support Care Cancer       Date:  2012-01-20       Impact factor: 3.603

Review 4.  Quality of life domains among non-Hodgkin lymphoma survivors: an integrative literature review.

Authors:  Ashley Leak; Deborah K Mayer; Sophia Smith
Journal:  Leuk Lymphoma       Date:  2011-05-03

5.  Health-care utilization by prognosis profile in a managed care setting: using the Surveillance, Epidemiology and End Results Cancer Survival Calculator SEER*CSC.

Authors:  Borsika A Rabin; Jennifer L Ellis; John F Steiner; Larissa Nekhlyudov; Eric J Feuer; Benjamin F Hankey; Laurie Cynkin; Elizabeth Bayliss
Journal:  J Natl Cancer Inst Monogr       Date:  2014-11

6.  Strength of skeletal muscle and quality of life in patients suffering from "typical male" carcinomas.

Authors:  Richard Crevenna; Bruno Maehr; Veronika Fialka-Moser; Mohammad Keilani
Journal:  Support Care Cancer       Date:  2009-06-12       Impact factor: 3.603

7.  Influence of health-related quality of life on health service utilization in addition to socio-demographic and morbidity variables among primary care patients in China.

Authors:  Tianhui Chen; Lu Li
Journal:  Int J Public Health       Date:  2009-08-13       Impact factor: 3.380

8.  Health care access and utilization among adult cancer survivors: Results from the National Institutes of Health "All of Us" Research Program.

Authors:  Steven S Coughlin; Jie Chen; Jorge E Cortes
Journal:  Cancer Med       Date:  2021-05-03       Impact factor: 4.452

Review 9.  An international review of the patterns and determinants of health service utilisation by adult cancer survivors.

Authors:  Charlene Treanor; Michael Donnelly
Journal:  BMC Health Serv Res       Date:  2012-09-13       Impact factor: 2.655

10.  Early complications following oesophagectomy for cancer in relation to long-term healthcare utilisation: a prospective population-based cohort study.

Authors:  Eva Doorakkers; Peter Konings; Fredrik Mattsson; Jesper Lagergren; Nele Brusselaers
Journal:  PLoS One       Date:  2015-03-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.